RESUMO
Autoimmune myasthenia gravis (MG) is the prototypic, antibody-mediated neuromuscular disease and is characterized by a decrease in the number of functional acetylcholine receptors (AChR) within the muscle end plate zone of the neuromuscular junction (NMJ). Although the pathophysiology of AChR-mediated myasthenia gravis has been extensively studied over the last 40 years since its original description by Patrick and Lindstrom (Science 180:871-872, 1973), less is known about the much more recently described muscle-specific kinase (MuSK) antibody-mediated MG. MuSK-MG has features clinically distinct from Ach-R MG, as well as a different pattern of response to treatment and a unique immunopathogenesis.
Assuntos
Autoanticorpos/imunologia , Miastenia Gravis , Receptores Proteína Tirosina Quinases/imunologia , Receptores Colinérgicos/imunologia , Humanos , Miastenia Gravis/diagnóstico , Miastenia Gravis/imunologia , Miastenia Gravis/terapiaRESUMO
BACKGROUND: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease affecting upper and lower motor neurons in the CNS and leading to paralysis and death. There are currently no effective treatments for ALS due to the complexity and heterogeneity of factors involved in motor neuron degeneration. A complex of interrelated effectors have been identified in ALS, yet systemic factors indicating and/or reflecting pathological disease developments are uncertain. The purpose of the study was to identify humoral effectors as potential biomarkers during disease progression. METHODS: Thirteen clinically definite ALS patients and seven non-neurological controls enrolled in the study. Peripheral blood samples were obtained from each ALS patient and control at two visits separated by 6 months. The Revised ALS Functional Rating Scale (ALSFRS-R) was used to evaluate overall ALS-patient functional status at each visit. Eleven humoral factors were analyzed in sera. Cytokine levels (GM-CSF, IL-1ß, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, and TNF-α) were determined using the Bio-Rad Bio-Plex® Luminex 200 multiplex assay system. Nitrite, a breakdown product of NO, was quantified using a Griess Reagent System. Glutathione (GSH) concentrations were measured using a Glutathione Fluorometric Assay Kit. RESULTS: ALS patients had ALSFRS-R scores of 30.5 ± 1.9 on their first visit and 27.3 ± 2.7 on the second visit, indicating slight disease progression. Serum multiplex cytokine panels revealed statistically significant changes in IL-2, IL-5, IL-6, and IL-8 levels in ALS patients depending on disease status at each visit. Nitrite serum levels trended upwards in ALS patients while serum GSH concentrations were drastically decreased in sera from ALS patients versus controls at both visits. CONCLUSIONS: Our results demonstrated a systemic pro-inflammatory state and impaired antioxidant system in ALS patients during disease progression. Increased levels of pro-inflammatory IL-6, IL-8, and nitrite and significantly decreased endogenous antioxidant GSH levels could identify these humoral constituents as systemic biomarkers for ALS. However, systemic changes in IL-2, IL-5, and IL-6 levels determined between visits in ALS patients might indicate adaptive immune system responses dependent on current disease stage. These novel findings, showing dynamic changes in humoral effectors during disease progression, could be important for development of an effective treatment for ALS.
Assuntos
Esclerose Lateral Amiotrófica/sangue , Esclerose Lateral Amiotrófica/diagnóstico , Progressão da Doença , Interleucina-2/sangue , Interleucina-5/sangue , Interleucina-6/sangue , Biomarcadores/sangue , Estudos de Casos e Controles , Feminino , Glutationa/sangue , Humanos , Interleucina-8/sangue , Masculino , Pessoa de Meia-Idade , Nitritos/sangue , PrognósticoRESUMO
INTRODUCTION: The purpose of this study was to measure and analyze motor unit number estimation (MUNE) values longitudinally in spinal muscular atrophy (SMA). METHODS: Sixty-two children with SMA types 2 and 3 were observed prospectively for up to 42 months. Longitudinal electrophysiological data were collected, including compound motor action potential (CMAP), single motor unit action potential (SMUP), and MUNE. RESULTS: Significant motor neuron loss and compensatory collateral reinnervation were noted at baseline. Over time, there was a significant mean increase in MUNE (4.92 units/year, P = 0.009), a mean decrease in SMUP amplitude (-6.32 µV/year, P = 0.10), and stable CMAP amplitude. CONCLUSIONS: The unexpected longitudinal results differ from findings in amyotrophic lateral sclerosis studies, perhaps indicating that compensatory processes in SMA involve new motor unit development. A better understanding of the mechanisms of motor unit decline and compensation in SMA is important for assessing novel therapeutic strategies and for providing key insights into disease pathophysiology.
Assuntos
Potenciais de Ação/fisiologia , Adaptação Fisiológica/fisiologia , Neurônios Motores/fisiologia , Músculo Esquelético/fisiopatologia , Atrofias Musculares Espinais da Infância/genética , Proteína 1 de Sobrevivência do Neurônio Motor/genética , Adolescente , Adulto , Criança , Pré-Escolar , Estudos de Coortes , Progressão da Doença , Eletromiografia , Éxons , Feminino , Deleção de Genes , Homozigoto , Humanos , Lactente , Modelos Lineares , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Músculo Esquelético/inervação , Estudos Prospectivos , Atrofias Musculares Espinais da Infância/fisiopatologia , Adulto JovemRESUMO
INTRODUCTION: Numerous methods for motor unit number estimation (MUNE) have been developed. The objective of this article is to summarize and compare the major methods and the available data regarding their reproducibility, validity, application, refinement, and utility. METHODS: Using specified search criteria, a systematic review of the literature was performed. Reproducibility, normative data, application to specific diseases and conditions, technical refinements, and practicality were compiled into a comprehensive database and analyzed. RESULTS: The most commonly reported MUNE methods are the incremental, multiple-point stimulation, spike-triggered averaging, and statistical methods. All have established normative data sets and high reproducibility. MUNE provides quantitative assessments of motor neuron loss and has been applied successfully to the study of many clinical conditions, including amyotrophic lateral sclerosis and normal aging. CONCLUSIONS: MUNE is an important research technique in human subjects, providing important data regarding motor unit populations and motor unit loss over time.
Assuntos
Pesquisa Biomédica/métodos , Contagem de Células/métodos , Eletrofisiologia/métodos , Neurônios Motores/citologia , Potenciais de Ação/fisiologia , Estimulação Elétrica , Humanos , Neurônios Motores/fisiologia , Condução Nervosa/fisiologia , Reprodutibilidade dos TestesAssuntos
Miosite de Corpos de Inclusão , Piper , Efeitos Psicossociais da Doença , Humanos , Miosite , Estados UnidosAssuntos
4-Aminopiridina/análogos & derivados , Doenças da Junção Neuromuscular/tratamento farmacológico , Produção de Droga sem Interesse Comercial , Médicos/psicologia , Bloqueadores dos Canais de Potássio/uso terapêutico , 4-Aminopiridina/uso terapêutico , Amifampridina , Humanos , Doenças da Junção Neuromuscular/economia , Produção de Droga sem Interesse Comercial/economia , Produção de Droga sem Interesse Comercial/métodosRESUMO
OBJECTIVE: Randomized, blinded trial of intramuscular gene transfer using plasmid vascular endothelial growth factor (VEGF) to treat diabetic polyneuropathy. METHODS: Diabetic patients with polyneuropathy were randomized to receive a VEGF-to-placebo ratio of 3:1. Three sets of injections were given at eight standardized sites adjacent to the sciatic, peroneal, and tibial nerves of one leg. Primary outcomes were change in symptom score at 6 months and a prespecified overall clinical and electrophysiological improvement score. Secondary outcomes were differences in symptoms, examination scores, visual analog pain scale, nerve conduction, and quantitative sensory testing. RESULTS: Thirty-nine patients received plasmid VEGF and 11 received placebo. Mean symptom score improved in both legs at 6 months, favoring VEGF over placebo (-1.2 +/- 0.5 vs -0.9 +/- 0.5; p < 0.01 after adjustment for change in the untreated leg) and compared with the untreated leg (-0.7 +/- 0.5; p = 0.02). The region of sensory loss and visual analog pain scale improved in the treated group (-1.5 vs -0.5; p = 0.01). Twelve of 39 VEGF versus 2 of 11 placebo patients met criterion for overall improvement. Other measures including nerve conduction potentials did not improve. There were 84 adverse events in VEGF patients, and 22 were serious; there were 51 events in placebo patients, and 2 were serious. INTERPRETATION: Intramuscular plasmid VEGF gene transfer improved diabetic neuropathic symptoms, meeting primary end-point criteria for efficacy but not affecting most secondary measures. Treatment was associated with more serious adverse events that did not reach statistical significance. These results are not conclusive but may justify further clinical study.
Assuntos
Neuropatias Diabéticas/terapia , Técnicas de Transferência de Genes , Terapia Genética/métodos , Fator A de Crescimento do Endotélio Vascular/genética , Fator A de Crescimento do Endotélio Vascular/uso terapêutico , Idoso , Estudos de Coortes , Neuropatias Diabéticas/metabolismo , Método Duplo-Cego , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Condução Nervosa/genética , Medição da Dor , Nervos Periféricos/fisiopatologia , Índice de Gravidade de Doença , Resultado do TratamentoRESUMO
We prospectively studied 64 patients with motor neuron disease (amyotrophic lateral sclerosis (ALS), familial ALS (fALS), progressive muscular atrophy (PMA) and primary lateral sclerosis (PLS)) using multiple point stimulation motor unit number estimation (MUNE), transcranial magnetic stimulation (TMS), proton magnetic resonance spectroscopic imaging (1H MRSI), diffusion tensor imaging (MRDTI), and clinical measures at baseline and every 3 months thereafter for 15 months. Substantial differences in MUNE were noted among the motor neuron disease subgroups (P = 0.0005) and mean values for each motor neuron disease subgroup were significantly lower vs. controls (ALS = 76, fALS = 80, PMA = 29, and PLS = 174) vs. the normal control average (267). MUNE correlated well with % FVC (r = 0.32; P = 0.01), manual muscle testing (r = 0.52; P < 0.0005), grip strength (r = 0.34; P = 0.007), and pinch strength (r = 0.49; P < 0.0005). Overall, MUNE showed the greatest significant change over time of any measure, clinical or otherwise, tested in this study (-2.35 linear trend % change per month, mean). MUNE clearly delineates lower motor neuron dysfunction, strongly correlates with important clinical functions (such as strength and respiration) and is a highly sensitive marker of disease progression over time. These features make MUNE an important tool for both the study of the pathophysiology of the motor neuron diseases, as well as an important measure for incorporation into future clinical trials.
Assuntos
Biomarcadores/metabolismo , Doença dos Neurônios Motores/patologia , Neurônios Motores/fisiologia , Adulto , Idoso , Idoso de 80 Anos ou mais , Análise de Variância , Eletromiografia , Feminino , Humanos , Estudos Longitudinais , Espectroscopia de Ressonância Magnética/métodos , Masculino , Pessoa de Meia-Idade , Doença dos Neurônios Motores/fisiopatologia , Prótons , Estatística como Assunto , Estimulação Magnética Transcraniana/métodosRESUMO
The parkinsonian variant of multiple system atrophy (MSA-P) can be difficult to differentiate from Parkinson's disease (PD). This Practice Point commentary discusses a multicenter study performed by the European MSA Study Group that sought to determine whether certain clinical features could serve as 'red flags', or warning signs, to assist in the early diagnosis of MSA-P. The study included 57 patients with probable MSA-P and 116 patients with probable PD. The presence of two out of six red-flag categories yielded 98.3% specificity and 84.2% sensitivity for a diagnosis of MSA-P as opposed to PD. In 13 of 17 patients with possible MSA-P who later progressed to probable MSA-P, use of the red-flag categories would have accelerated the diagnosis of probable MSA-P by an average of 15.9 months. Although this study has several limitations, the identified red-flag categories may be useful as supportive criteria in diagnosing probable MSA-P.
RESUMO
Electrodiagnostic studies are a critical tool for the identification and study of peripheral neuropathy, enabling definition of the pathophysiologic type of nerve injury, its distribution, severity, and the degree of motor or sensory nerve involvement. These data help to differentiate the varieties of neuropathy from other neuromuscular diseases. Nerve conduction studies and electromyography, although widely performed, are complex techniques and are subject to a wide range of artifacts, which can result in missed or erroneous diagnoses. Without proper education, training, and experience in neuromuscular disease and the techniques of electrodiagnosis and careful attention to potential sources of error, the critical information needed to properly diagnose and treat patients with neuropathy is unreliable and may lead to wasted resources and patient injury.
Assuntos
Doenças do Sistema Nervoso Periférico/diagnóstico , Idoso , Doenças Desmielinizantes/diagnóstico , Doenças Desmielinizantes/fisiopatologia , Eletromiografia/instrumentação , Humanos , Condução Nervosa/fisiologia , Doenças do Sistema Nervoso Periférico/fisiopatologia , TemperaturaRESUMO
INTRODUCTION: Friedreich's Ataxia (FA) is a devastating, progressive, neurodegenerative disease. Objective measures that detect changes in neurological function in FA patients are needed to facilitate therapeutic clinical trials. The purpose of this pilot study was to analyze longitudinal changes in gait and balance in subjects with FA using the GAITRite Walkway System® and Biodex Balance System™, respectively, and to test the ability of these measures to detect change over time compared to the Friedreich's Ataxia Rating Scale (FARS). METHODS: This was a 24-month longitudinal study comparing ambulatory FA subjects with age- and gender-matched, healthy controls. Eight FA subjects and 8 controls were tested at regular intervals using the GAITRite and Biodex Balance systems and the FARS. RESULTS: In the FA group, comfortable and fast gait velocity declined 8.0% and 13.9% after 12 months and 24.1% and 30.3% after 24 months, respectively. Postural stability indices increased in FA subjects an average of 41% from baseline to 24 months, representing a decline in balance. Subjects with FA also demonstrated a 17.7% increase in FARS neurological exam scores over 24 months. There were no changes in gait or balance variables in controls. In the FA group, multiple gait and balance measures correlated significantly with FARS neurological exam scores. CONCLUSIONS: The GAITRite and Biodex Balance systems provided objective and clinically relevant measures of functional decline in subjects with FA that correlated significantly with performance measures in the FARS. Gait velocity may be an important objective measure to identify disease progression in adults with FA.
Assuntos
Ataxia de Friedreich/fisiopatologia , Marcha/fisiologia , Equilíbrio Postural/fisiologia , Caminhada/fisiologia , Adulto , Progressão da Doença , Feminino , Ataxia de Friedreich/diagnóstico , Humanos , Estudos Longitudinais , Masculino , Exame Neurológico , Projetos Piloto , Índice de Gravidade de DoençaRESUMO
OBJECTIVE: To describe a patient with multifocal motor neuropathy with conduction block who had annual clinical and physiological examinations for 18 years but declined treatment for personal reasons. DESIGN: Case report. SETTING: Collaboration between 2 academic tertiary care hospitals. Patient One patient with multifocal motor neuropathy with conduction block. RESULTS: At age 44 years, there was weakness and wasting of the left biceps with conduction block in the left musculocutaneous and right ulnar nerves. The left median nerve was inexcitable. The right median, ulnar, and left peroneal nerves developed axonal change (loss of distal compound muscle action potential amplitude) at years 5, 12, and 13. By 2005, new weakness had appeared in 20 muscles (16 in the arms); he could not use a keyboard, button buttons, or write his name. Nerves that initially showed conduction block became inexcitable over the course of the illness. CONCLUSIONS: Multifocal motor neuropathy with conduction block is a disease that may be "only" slowly progressive but is not always benign. Nerves showing conduction block may develop axonal change. Better markers for this disease are needed.
Assuntos
Doença dos Neurônios Motores/patologia , Condução Nervosa/fisiologia , Potenciais de Ação/fisiologia , Adulto , Braço/inervação , Braço/fisiologia , Eletromiografia , Humanos , Imunização Passiva , Masculino , Doença dos Neurônios Motores/fisiopatologia , Músculo Esquelético/fisiopatologia , Exame Neurológico , Nervos Periféricos/fisiopatologia , Recusa do Paciente ao TratamentoRESUMO
BACKGROUND: Mitochondrial DNA point mutations are especially deleterious to tissues with high energy demand, including the peripheral nervous system. Neuropathy has been associated with several mitochondrial diseases, including MELAS (mitochondrial encephalomyopathy, lactic acidosis, and strokelike episodes). OBJECTIVE: To evaluate nerve conduction in a genotypically and phenotypically homogeneous group of patients with MELAS and the A3243G mutation. DESIGN: We studied 30 patients with MELAS and the A3243G mutation using neurophysiological techniques, medical history questionnaires, laboratory tests, and a standardized neurological examination. RESULTS: Twenty-three subjects (77%) had abnormal nerve conduction measures. Symptoms suggestive of neuropathy were present in only half of the patients, but almost all had decreased reflexes or distal sensory findings on examination. Nerve conduction abnormalities were predominantly axonal and sensory and mainly present in the legs. Patients with nerve conduction abnormalities tended to be older and were more likely male. CONCLUSIONS: Peripheral nerve impairment is common in those with MELAS and the A3243G mutation, and may be subclinical. Male sex and older age may add to the genetic disposition to develop neuropathy.
Assuntos
DNA Mitocondrial/genética , Síndrome MELAS/genética , Síndrome MELAS/fisiopatologia , Condução Nervosa/fisiologia , Mutação Puntual , Adulto , Análise Mutacional de DNA/métodos , Estimulação Elétrica/métodos , Feminino , Humanos , Masculino , Exame Neurológico/métodos , Sistema Nervoso Periférico/fisiopatologia , Sistema Nervoso Periférico/efeitos da radiação , Inquéritos e QuestionáriosRESUMO
Since its introduction 30 years ago, MUNE technologies have been increasingly refined and applied to a wide variety of neuromuscular disorders. Differences of opinion remain among MUNE investigators as to which method should be used; however, statistical and MPS MUNE currently enjoy the most widespread use. A number of methodological issues remain, including the development of detailed universal standards for each technique and modifications for the further enhancement of reproducibility. These issues are the subject of ongoing investigation. However, despite technical variability, the MUNE values obtained with different methods show good agreement, both in studies of healthy subjects and in patients with a variety of neurogenic processes. MUNE has been most successfully applied to patients with ALS and in animal models of motor neuron disease, providing significant insight into the pathophysiology of these disorders. These techniques are being increasingly incorporated into clinical therapeutic trials. MUNE is a technology offering important promise in the study of neuromuscular disease, enabling the collection of novel data in the living patient unobtainable by any other method.